Yes, there were shares of restricted stock for executive officers that vested on FDA approval of generic Lovenox. (These shares were issued at various times in 2006 and 2007—see below.) The awarding of restricted stock that vests on FDA approval of generic Copaxone is presumably being done now because the Lovenox restricted stock, having already vested, no longer provides a performance incentive beyond the incentive from share ownership per se.
News 
Market Data 
Discover 
AI
